Primobolan

No summary available for this substance.

Primobolan

Primobolan, also known as Methenolone, is an anabolic steroid, often used by bodybuilders and athletes for performance enhancement. It is known for its mild anabolic effects and minimal androgenic side effects, making it popular among those who are particularly sensitive to the androgenic effects of steroids.

Category
Anabolic Steroid
Molecular Formula
C20H30O2
Mechanism of Action
Primobolan works by increasing the amount of protein that is produced by your body, which can lead to increased muscle mass and strength. It also helps the body to retain nitrogen, which enhances the effects of other anabolic substances.
Evidence Grade
C - Unclear scientific evidence for this use

Other Names

  • Methenolone
  • Methenolone Enanthate
  • Methenolone Acetate

Primary Benefits

  • Increases muscle mass
  • Improves strength
  • Boosts performance

Recommended Dosage

Men 300-800mg per week
Women 50-100mg per week

Side Effects

  • Acne
  • Hair loss
  • Liver damage
  • Menstrual problems
  • Changes in libido

Precautions

  • Not recommended for those with liver problems
  • Not recommended during pregnancy or breastfeeding
  • Regular blood tests required
  • Not recommended for those with heart disease

Interactions

  • Warfarin
  • Insulin
  • Oral antidiabetic drugs

Key References

  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837307/
  • https://pubchem.ncbi.nlm.nih.gov/compound/Methenolone
  • https://www.sciencedirect.com/science/article/pii/S037907380000165X
335 ‒ The science of resistance training, building muscle, and anabolic steroid use in bodybuilding
Strategies for Building Lean Muscle, Hormone Balance, and Nutrition 1:54:59 0
“if someone's like way too much estrogen for them they can do a 50/50 split of testosterone primobolan so that now they get all the good estrogen from testosterone but not too much of it but they get most of that anabolic drive from the rest of the primobolan but without any more estrogen addition”

No comments yet.

View all comments (0)